General Dermatology

Dermatology Times is recapping our top expert interviews from the month of January.

James Del Rosso, DO, shared insights on existing and upcoming therapies for seborrheic dermatitis.

Explore the top headlines of the week including clinical trial updates, social media hair trends, and expert insights.

In case you missed it, this week we had news about the link between psoriasis and dementia, the future of urticaria treatment, VP-315's positive results in basal cell carcinoma, and more.

Personalized care is key to managing hyperhidrosis, blending therapies, addressing adverse effects, and empowering patients with tailored solutions.

Understanding urticaria subtypes, from spontaneous to inducible, is key to crafting patient-specific management plans.

According to a phase 3 study, the omalizumab biosimilar saw comparable results with a good safety profile.

In his presentation at Winter Clinical Miami, Del Rosso covered new and emerging therapies as well as successful off-label uses.

Attovia is also advancing 4 ATTOBODY-based programs for inflammatory conditions, such as atopic dermatitis and IBD.

Adam Friedman, MD, FAAD, takes a closer look at the emerging landscape of oral treatments for hyperhidrosis and what lies ahead in advancing patient care.

Jason Hawkes, MD, MS, discusses unmet needs in chronic urticaria care and challenges outdated testing practices.

Fast-acting therapies like remibrutinib bring new hope to patients with chronic urticaria who don’t respond to antihistamines.

Hawkes combines personal experience and clinical expertise to treat urticaria patients.

Explore the top headlines of the week including the growth of NPs and PAs in the field, clinical trial updates, and advancements in therapy.

In case you missed it, this week we had news about AIs and CNNs for early melanoma detection, OCT Technology for vitiligo imaging, UCB’s 320mg single-injection bimekizumab, and more.

A recent study evaluated the efficacy of low-energy delicate pulsed light photomodulation for treating sensitive skin, showing significant improvements in symptoms and erythema.

Mitragotri's work bridges advanced drug development and skin care for tailored treatments.

The new dosing option offers convenience for those managing plaque psoriasis, PsA, and hidradenitis suppurativa.

Soligenix recently shared interim results from a 12-month investigator-initiated study of synthetic hypericin.

A study found that UK adults living with psoriasis and vitiligo were better able to self-manage the psychological implications of their condition.

In case you missed it, this week we had news about phase 2b enrollment for VYNE’s vitiligo gel, the impact of anti-inflammatory moisturizers for AD, the newly FDA-approved DermiSphere hDRT, and more.

Explore the top headlines of the week including clinical trial updates, FDA announcements, and expert insights.

Advancements in therapeutic agents demand innovative strategies for safe, localized skin treatments, Mitragotri argues.

Mitragotri said new innovations like ionic liquid-based delivery systems can offer better treatment for immunodermatological conditions.

UVF dermoscopy enhances scabies detection, especially in dark skin, with optimal results when combined with polarized light examination.

The innovative technology is unlocking new possibilities in dermatology by improving the solubility and permeability of drugs for topical use.

Palvella begins its phase 2 TOIVA trial of Qtorin rapamycin gel for cutaneous venous malformations, targeting the mTOR pathway.

While zinc deficiency shows strong ties to SD, researchers stated vitamin D's role is less clear and may depend on genetic factors.

By addressing skin health proactively, runners can enhance performance and longevity in the sport while minimizing discomfort and long-term dermatological damage.

Share your insights and anticipation with us.